CRD 3874
Alternative Names: CRD-3874; CRD3874-SILatest Information Update: 28 Sep 2026
At a glance
- Originator Curadev Pharma
- Developer Curadev Pharma; Memorial Sloan-Kettering Cancer Center; University of Maryland, Baltimore
- Class Antineoplastics; Small molecules
- Mechanism of Action STING1 protein stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia
- Preclinical Solid tumours
- No development reported Merkel cell carcinoma; Sarcoma
Most Recent Events
- 28 Sep 2026 No recent reports of development identified for phase-I development in Merkel cell carcinoma(Late-stage disease, Metastatic disease) in USA (IV, Infusion)
- 28 Sep 2026 No recent reports of development identified for phase-I development in Sarcoma(Late-stage disease, Metastatic disease) in USA (IV, Infusion)
- 15 Jun 2026 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA (IV) (NCT07661095)